DOJ Reports Record Fiscal Year 2025 False Claims Act Recoveries
March 02, 2026What FDA-Regulated Companies Should Take Away (Beyond the Headline)
On January 16, 2026, the U.S. Department of Justice announced that False Claims Act (FCA) settlements and judgments for Fiscal Year 2025 exceeded $6.8 billion, the highest annual total in the statute’s history. Recoveries more than doubled FY 2024 results, driven overwhelmingly by healthcare enforcement. The FY 2025 results reflect not only higher recoveries but also a DOJ enforcement posture increasingly comfortable advancing broader FCA theories tied to compliance representations, operational controls, and corporate decision-making.
For medical device, pharmaceutical, and other FDA-regulated companies, the headline figure matters less than what it reflects: broader FCA theories, continued reliance on whistleblowers, and closer scrutiny of how compliance representations align with operational reality. The FY 2025 results make clear that FCA risk is no longer episodic or limited to billing errors. It is increasingly tied to enterprise-wide decision-making.
The Enforcement Story Behind the Numbers
Healthcare accounted for approximately $5.7 billion (83%) of all FCA recoveries, confirming that life sciences remains DOJ’s primary enforcement focus. At the same time, a record 1,297 qui tam actions were filed, underscoring that whistleblowers remain the primary engine of FCA enforcement and often surface issues well before companies identify them internally.
DOJ has also continued to expand the framing of FCA liability. Billing allegations are frequently paired with assertions relating to medical necessity, quality of care, pricing and discount practices, or contractual and compliance certifications. For FDA-regulated companies, FCA exposure is rarely confined to a single department and often arises from the intersection of regulatory, reimbursement, quality, and commercial functions.
Practical Takeaways for FDA-Regulated Companies
The FY 2025 results highlight several realities that should inform compliance strategy going forward.
First, FCA risk is no longer confined to billing or reimbursement teams. Pricing, market access strategies, reimbursement support programs, cybersecurity representations (including contractual and regulatory attestations), clinical and quality practices, and commercial communications all influence the representations that DOJ later evaluates through an FCA lens.
Second, compliance programs are judged by performance, not presence. Written policies and training alone are insufficient. DOJ scrutiny often centers on whether companies identified risks early, escalated concerns appropriately, and implemented timely, documented corrective action when issues emerged.
Third, documentation remains a decisive factor. Many FCA matters hinge on whether internal communications, certifications, or operational practices can be portrayed as materially false or misleading. Clear, contemporaneous documentation of decision-making, risk assessments, and remediation efforts is often the strongest defense.
Finally, whistleblower preparedness is critical. With qui tam filings at an all-time high, companies should assume that unresolved internal concerns may eventually be raised externally. Strong internal reporting mechanisms, prompt investigations, and visible remediation materially reduce that risk. Many recent FCA matters trace back to internal concerns that were raised but not fully investigated, escalated, or documented, underscoring the importance of disciplined response processes.
DOJ’s FY 2025 results underscore that FCA risk increasingly depends on how companies operate, document, and respond, even where they do not submit claims directly but instead influence downstream billing.
Looking Ahead
DOJ’s record FY 2025 recoveries signal an enforcement environment that is only intensifying. For FDA-regulated companies, FCA exposure increasingly turns on how well compliance programs operate in practice and how effectively regulatory, reimbursement, and commercial strategies remain aligned under scrutiny.
Companies should use this moment to reassess risk areas, test whether existing controls are functioning in practice, and close gaps before they escalate into enforcement issues.
How Gardner Law Can Help
Gardner Law works with medical device, pharmaceutical, diagnostics, and life sciences companies to help identify, assess, and mitigate FCA risk before it escalates into government inquiries or whistleblower-driven litigation. Our approach is practical, risk-based, and tailored to how FDA-regulated companies actually operate.
We regularly assist clients with targeted FCA and reimbursement risk assessments, evaluation of pricing and market access strategies, review of reimbursement support and patient assistance programs, compliance program stress-testing, internal investigations, whistleblower response planning, and board-level training on FCA enforcement trends.
If your organization would benefit from a focused assessment of FCA exposure, such as a targeted review of pricing practices, reimbursement support programs, internal controls, and escalation processes, we welcome the opportunity to discuss how Gardner Law can support your risk-management and compliance objectives.